Skip to main content

Table 2 Comparison of clinicopathological features between patients with Mt and Wt

From: Impact of the epidermal growth factor receptor mutation status on the prognosis of recurrent adenocarcinoma of the lung after curative surgery

Total n = 237 Mt (n = 108) Wt (n = 129) P valuesa
Age 66.5 66.1 0.791b
Male, (%) 48 (44.4) 85 (65.9) 0.001
Smoking history, (%) 52 (48.1) 94 (72.9) < 0.001
Surgical procedure, (%)
 pneumonectomy 2 (1.9) 3 (2.3)  
 lobectomy 104 (96.2) 124 (96.1)  
 segmentectomy 2 (1.9) 2 (1.6) 0.958
Pathological tumor size, (mm) 33.9 (11–100) 40.0 (11–210) 0.019b
Pathological stage, (%)
 I 24 (22.2) 36 (27.9)  
 II 26 (24.1) 36 (27.9)  
 III 58 (53.7) 57 (44.2) 0.337
Lymphatic invasion, (%) 61 (56.4) 58 (45.0) 0.077
Vascular invasion, (%) 68 (63.0) 83 (64.3) 0.826
Pleural invasion, (%) 50 (46.3) 72 (55.8) 0.144
Nodal invasion, (%) 81 (75.0) 80 (62.0) 0.033
Recurrence pattern
 locoregional 29 (26.9) 43 (33.3)  
 systemic 79 (73.1) 86 (66.7) 0.280
Administration of EGFR - TKI 81 (75.0) 7 (5.4) < 0.001
  1. aFisher’s exact test
  2. bStudent’s t-test
  3. Mt EGFR mutant, Wt EGFR wild-type, TKI tyrosine kinase inhibitor